GlassScriptPhysician profile
Rudolph A Bedford
NPI 1902885684
$18,188.48
in general payments reported to CMS, 2019-2025
44 companies · $4,981 in 2025
The $4,981 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $1,114 · 2021: $2,999 · 2022: $3,030 · 2023: $2,433 · 2024: $2,450 · 2025: $4,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,312 · Consulting Fee: $1,071 · Travel and Lodging: $429 · Education: $52.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,312.02 |
| Consulting Fee | $1,071.43 |
| Travel and Lodging | $428.57 |
| Education | $52.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,933.37 | 2019-2025 | Skyrizi, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,892.72 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Olympus Medical Systems Corporation | $1,500.00 | 2025 | Evis Exera II Ultrasound Gastrovideoscope |
| Janssen Biotech, INC. | $1,136.72 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $611.90 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $522.01 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $502.89 | 2019-2024 | Dificid |
| Pfizer INC. | $497.06 | 2019-2025 | |
| Gilead Sciences, INC. | $446.31 | 2019-2025 | Livdelzi |
| Qol Medical, LLC | $409.56 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $388.97 | 2022-2025 | |
| Lilly USA, LLC | $347.87 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $316.25 | 2021-2023 | |
| Ardelyx, INC. | $299.98 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $286.17 | 2021-2024 | Exalt Model D, Spyglass, Compliance Endokit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rudolph Bedford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.